These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 582113)

  • 21. Effect of L-threo-3,4-dihydroxyphenylserine (L-DOPS) on catecholamine levels in plasma and cerebrospinal fluid (CSF) in anesthetized rats.
    Ishikawa Y; Kato Y; Murakami Y; Inoue T; Koshiyama H; Imura H
    Proc Soc Exp Biol Med; 1987 Feb; 184(2):197-200. PubMed ID: 3101067
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of L-threo-3,4-dihydroxyphenylserine (L-DOPS), an immediate precursor of norepinephrine, on the cerebral blood flow in rats.
    Sato E; Irie T; Katsube J
    Jpn J Pharmacol; 1987 Jan; 43(1):91-3. PubMed ID: 3106684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [L-threo-DOPS therapy and parkinsonism].
    Narabayashi H
    No To Shinkei; 1986 Jan; 38(1):60-2. PubMed ID: 3083844
    [No Abstract]   [Full Text] [Related]  

  • 24. Effects of L-threo- and erythro-3,4-dihydroxyphenylserine on learning performance and concentrations of brain noradrenaline and its metabolites in rats.
    Harada H; Noto T; Tsuji M; Taga C; Hashimoto H; Nakajima T
    Pharmacol Biochem Behav; 1992 Sep; 43(1):215-21. PubMed ID: 1409807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibitory effect of (+)threo-3,4-dihydroxy-phenylserine (DOPS) on decarboxylation of (-)threo-dops.
    Inagaki C; Fujiwara H; Tanaka C
    Jpn J Pharmacol; 1976 Jun; 26(3):380-2. PubMed ID: 978852
    [No Abstract]   [Full Text] [Related]  

  • 26. Norepinephrine precursor therapy in neurogenic orthostatic hypotension.
    Kaufmann H; Saadia D; Voustianiouk A; Goldstein DS; Holmes C; Yahr MD; Nardin R; Freeman R
    Circulation; 2003 Aug; 108(6):724-8. PubMed ID: 12885750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Synthesis of (-) or (+) -threo-3-(3,4-dihydroxyphenyl) serine and (-) or (+) -erythro-3-(3,4-dihydroxyphenyl)-serine].
    Hegedüs B; Krassó AF; Noack K; Zeller P
    Helv Chim Acta; 1975 Jan; 58(1):147-62. PubMed ID: 1158718
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparative effects of 1-ethyl- and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridines on catecholamine concentrations in mouse brain and heart.
    Fuller RW; Hemrick-Luecke SK; Robertson DW
    Res Commun Chem Pathol Pharmacol; 1988 Jan; 59(1):129-32. PubMed ID: 3258433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Catecholamine metabolism during additional administration of DL-threo-3,4-dihydroxyphenylserine to patients with Parkinson's disease.
    Teelken AW; van den Berg GA; Muskiet FA; Staal-Schreinemachers AL; Wolthers BG; Lakke JP
    J Neural Transm Park Dis Dement Sect; 1989; 1(3):177-88. PubMed ID: 2476157
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of the novel dopamine beta-hydroxylase inhibitor SK&F 102698 on catecholamines and blood pressure in spontaneously hypertensive rats.
    Berkowitz BA; Arleth AJ; Sung CP; Kruse LI; DeWolf WE; Ohlstein EH
    J Pharmacol Exp Ther; 1988 Jun; 245(3):850-7. PubMed ID: 3385645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased brain concentration of homovanillic acid in rats treated with threo-3,4-dihydroxyphenylserine.
    Edwards DJ; Sedlock ML
    J Pharm Pharmacol; 1982 Oct; 34(10):685-6. PubMed ID: 6128399
    [No Abstract]   [Full Text] [Related]  

  • 32. [Inhibitory effects of L-threo-DOPS on electroshock seizure in mice].
    Yoshida M; Nakanishi T
    No To Shinkei; 1989 Jun; 41(6):567-73. PubMed ID: 2508734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. L-Dihydroxyphenylserine (L-DOPS): a norepinephrine prodrug.
    Goldstein DS
    Cardiovasc Drug Rev; 2006; 24(3-4):189-203. PubMed ID: 17214596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of brain catecholamine synthesis and release of prolactin and luteinizing hormone in the ovariectomized rat.
    Carr LA; Conway PM; Voogt JL
    J Pharmacol Exp Ther; 1975 Jan; 192(1):15-21. PubMed ID: 1123720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modification of the cardiovascular effects of L-dopa by decarboxylase inhibitors.
    Watanabe AM; Parks LC; Kopin IJ
    J Clin Invest; 1971 Jun; 50(6):1322-8. PubMed ID: 5578236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diuretic effect of L-threo-3,4-dihydroxyphenylserine, a noradrenaline precursor, in rats and mice.
    Katsube J; Kato T; Katsuyama M; Maeda Y; Nishikawa S; Nakamura M
    J Pharm Pharmacol; 1986 Jul; 38(7):533-4. PubMed ID: 2875157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of effects of chlordecone on synthesis rates, steady state levels and metabolites of catecholamines in rat brain.
    Aldous CN; Chetty CS; Mehendale HM; Desaiah D
    Neurotoxicology; 1984; 5(2):59-65. PubMed ID: 6209598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Age-related changes in the chronotropic effect and the enzymic decarboxylation of L-threo-3,4-dihydroxphenylserine in the rat heart.
    Araki H; Fujiwara H; Tanaka C
    J Pharm Pharmacol; 1981 Dec; 33(12):778-82. PubMed ID: 6121849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Uptake of L-threo-dihydroxyphenylserine into human brain synaptosomes.
    Naoi M; Nagatsu T
    J Neural Transm; 1987; 70(1-2):51-61. PubMed ID: 3117973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Behavior of fluorinated analogs of L-(3,4-dihydroxyphenyl)alanine and L-threo-(3,4-dihydroxyphenyl)serine as substrates for Dopa decarboxylase.
    Borri Voltattorni C; Bertoldi M; Bianconi S; Deng WP; Wong K; Kim I; Herbert B; Kirk KL
    Biochem Biophys Res Commun; 2002 Jul; 295(1):107-11. PubMed ID: 12083775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.